Vivo Capital
About Vivo Capital
Vivo Capital is a global healthcare investment specialist with a multi-strategy platform spanning venture capital, private equity and public equity investments. The firm focuses on expanding healthcare access and catalyzing innovation through its Ecosystem Strategy, supporting companies across the global healthcare landscape. Headquartered to serve a worldwide market, Vivo Capital emphasizes strong track records in IPOs, M&A, and regulatory approvals to drive growth in bioscience and pharmaceutical sectors.
Recent News
Oricell Therapeutics Secures $110 Million Pre‑IPO Funding, Spotlighting Investment Banking Activity
Legends Lost: Baltimore, Rutter Among Biotech’s Greats to Depart in 2025
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Oricell Therapeutics Secures $110 Million to Take on One of Oncology's Most Vexing Problems
Oricell Closes a ‘Pre-IPO’ Megaround to Aim CAR-T at Solid Tumors
Genentech, SanegeneBio Launch Up-to-$1.7B RNAi Collaboration
BlossomHill Therapeutics Inks $84M Series B Extension
EpiBiologics Closes $107M Series B
Recent Deals
BlossomHill Therapeutics Secures $84M Series B Extension Funding
Immunic Raises up to $400M in Oversubscribed Private Placement
AN2 Therapeutics Raises $40M in Private Placement Financing
BlossomHill Therapeutics Secures $84M Series B Extension
